NR-51636 结核分枝杆菌

NR-51636??Mycobacterium tuberculosis, Delamanid (Reference Standard)(Antimicrobial Compounds and Other Chemicals)|Mycobacterium tuberculosis|Delamanid (Reference Standard)|Room temperature, protected from light|N HariguchiAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Delamanid (Reference Standard), NR-51636.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. This item is currently in our production queue. Please allow ample time for distribution lots to be made available. NR-51636 is subject to the Material Transfer Agreement Registration Addendum attached to the Additional Information section below. NR-51636 may not be used for commercial purposes. It may only be used for in vitro studies of mycobacteria drug susceptibility testing, in vitro pharmacokinetic/pharmacodynamic studies including the Hollow Fiber System (HFS) and/or animal studies of mycobacterial infection models. Delamanid (OPC-67683; Deltyba?) is a bicyclic nitro-imidazooxazole compound shown to be effective against Mycobacterium tuberculosis (M. tuberculosis), through inhibiting the synthesis of key mycolic acids. Among TB drugs, delamanid has the lowest minimum inhibitory concentration (MIC) against both drug-susceptible and drug-resistant M. tuberculosis isolates, and is active against replicating and dormant, extracellular and intracellular bacilli. In clinical studies, delamanid demonstrated significant improvement of sputum culture conversion with two months of treatment in combination with an optimized background regimen for pulmonary multidrug-resistant (MDR)-TB adult patients, as compared to treatment with placebo. Spontaneous resistance frequencies to delamanid were similar to those of isoniazid and PA-824. Each vial contains approximately 20 mg of delamanid. For research use only. Not for human use.